Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Protara Therapeutics, Inc.NASDAQ: TARA
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$90K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$90K.
Context
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$90K or moves back toward the trailing-twelve-month quarterly average of -$22.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (362K) USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (362K) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (341K) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Gross Profit vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 gross profit of -$90K is the lowest of the 10 companies compared; the peer median is $16.33M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $65.55M | +83.9% | -15.3% | 83.9% | |
| LTM Mar 2026 | $51.41M | +50.2% | — | 92.0% | |
| LTM Mar 2026 | $34.56M | -45.8% | -31.5% | 100.0% | |
| LTM Mar 2026 | $32.49M | +1115.8% | +118.1% | 99.3% | |
| LTM Mar 2026 | $16.33M | +133.3% | — | 97.7% | |
| LTM Mar 2026 | $10.25M | -61.7% | — | 35.5% | |
| LTM Mar 2026 | $2.84M | +2.7% | -37.2% | 19.6% | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Mar 2026 | -$31.98K | — | — | — | |
| LTM Mar 2026 | -$90K | — | — | — | |
| Peer median (excluding TARA) | $16.33M | +50.2% | -23.4% | 92.0% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 341K | 0 | 362K |
| Gross Profit | 0 | 0 | (341K) | 0 | (362K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M |
| Selling, General & Admin | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M |
| Operating Expenses | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| EBITDA | (45.4M) | (64.57M) | (40.08M) | (44.26M) | (57.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (47.49M) | (67.06M) | (43.61M) | (49.15M) | (64.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 237K | 1.11M | 2.73M | 4.14M | 6.33M |
| Interest Expense | 1.74M | 1.14M | 0 | 0 | 0 |
| Other Income / Expenses | 237K | 1.11M | 3.19M | 4.56M | 7.11M |
| Income Before Tax | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| EPS (Diluted) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| Weighted Avg Shares | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
| Weighted Avg Shares (Diluted) | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.